Avalo Therapeutics AVTX 深 滬
等待開盤 09-24 09:30:00 美东时间
15.30
-1.210
-7.33%
華盛通- 最 高16.49
- 今 開16.40
- 成交量 111.12万股
- 最 低 15.13
- 昨 收 16.51
- 總市值 8.21亿
- 52周最高 24.27
- 市盈率 靜 --
- 換手率 2.07%
- 52周最低 12.51
- 委 比 12.63%
- 總股本 5363.00万
- 歷史最高 22032.00
- 量 比 0.86
- 振 幅 8.24%
- 歷史最低 3.39
- 每 手 1
- 風險率 2.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Avalo Therapeutics To Present Abdakibart Data At EADV Congress 2026
Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vie...
09-23 19:07
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics granted inducement equity awards to six new employees, including nonstatutory stock options for 78,000 shares with an exercise price of $19.34 per share. The options vest 25% after one year and monthly over the next 36 months, subject to continued employment. Avalo is advancing its anti-IL-1β monoclonal antibody, abdakibart, in a phase 3 trial for hidradenitis suppurativa and developing AVTX-010, a next-generation anti-IL-1β mA...
09-04 20:05
LB Pharmaceuticals appoints Joseph Miller as CFO
LB Pharmaceuticals (LBRX) announced on Thursday the appointment of Joseph Miller as chief financial officer, or CFO. Before joining LB Pharmaceuticals, Miller served as CFO of Aurinia Pharmaceuticals....
09-03 20:37
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
LB Pharmaceuticals has appointed Joseph Miller as its Chief Financial Officer. With over 20 years of experience in biopharmaceutical finance, Miller brings expertise in financial strategy, operations, and organizational growth. His appointment coincides with the company's pivotal NOVA-2 clinical trial for LB-102, a potential schizophrenia treatment. Miller's leadership at Aurinia Pharmaceuticals and Avalo Therapeutics, where he successfully scale...
09-03 12:00
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics announced its participation in several investor conferences in September 2026, including the Cantor Global Healthcare Conference, Morgan Stanley's Global Healthcare Conference, H.C. Wainwright's Global Investment Conference, and Stifel's Immunology and Inflammation Forum. The company focuses on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases, with its lead candidate abdakibart in a pha...
09-03 11:00
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $35 to $30.
08-07 19:07
Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.58) by 43.1 percent. This is a 56.77 percent increase over losses of $(1.92) per share from the same period last year.
08-06 19:46
美股大行评级 | 高盛上调AMD目标价从450美元升至640美元；伯恩斯坦上调阿斯麦目标价从1971美元升至2623美元
今日重点评级关注：Roth Capital：维持Nuvectis Pharma"买入"评级，目标价从20美元升至33美元；摩根士丹利：维持GXO Logistics"超配"评级，目标价从75美元升至78美元
07-07 11:34
Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38
Leerink Partners analyst Thomas Smith initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $38.
07-06 20:11
